Ideaya plans to submit an investigational new drug application next year for IDE034, a B7H3/PTK7 topo-I-payload bispecific antibody-drug conjugate.

The biomarker assay can be used potentially to enrich clinical trials and monitor patients' disease activity and treatment response.

NEW YORK – Canhelp Genomics on Monday said it is collaborating with Mirxes Singapore to provide solid tumor origin identification testing services in Singapore, Malaysia, Thailand, Indonesia, and the ...

The agency reviewed data from the FELIX trial, in which 63 percent of patients achieved a complete remission on the cell therapy at any time point.

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

The partners are advancing a pipeline of engineered DNase I therapies designed to work with CAR T cells to kill tumor cells.

RP-L102, which the firm designed to treat a form of disease caused by FANCA mutations, is already under review with the European Medicines Agency.

NEW YORK – The Children's Hospital of Philadelphia (CHOP) on Thursday announced a partnership with the Brazilian National Cancer Institute (INCA) to expand access to CAR T-cell therapies among ...

The restructuring is aimed at freeing up resources so the firm can advance its EBV-positive peripheral T-cell lymphoma drug toward the market.

SRP-5051 is designed to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations amenable to exon 51 skipping. With this ...

The company will use the proceeds to develop its gene therapies for eye disorders and for general corporate expenses.

Relevant genes to test for hereditary prostate cancer include ATM, BRCA1, BRCA2, CHEK2, HOXB13, and TP53, according to the guidelines. For all four cancer types included in these guidelines, NCCN also ...